AMENDMENTS TO THE CLAIMS:

1. (currently amended) A pharmaceutical formulation ~~for parenteral administration~~ containing complexes of cationic liposomes constituted of phospholipids and polydeoxyribonucleotides having a molecular weight in the range 15,000-60,000 Da, said polydeoxyribonucleotides obtained by depolymerization of nucleic acids, in the complexes the polydeoxyribonucleotides being located on the outer surface of the liposome.

2. (previously amended) The pharmaceutical formulation according to claim 1 having an anti-inflammatory activity.

3. (previously amended) The pharmaceutical formulation according to claim 1 having an anti-thrombotic activity.

4. (previously amended) The pharmaceutical formulation according to claim 1 having an anti-hypertensive activity.

5. (previously amended) The pharmaceutical formulation according to claim 1 for the therapy of pathologies the treatment of which requires a sustained release of the endothelial prostacyclin.

6. (previously amended) The pharmaceutical formulation according to claim 1 wherein the polydeoxyribonucleotide is defibrotide.

7. (previously amended) The pharmaceutical formulation according to claim 6 wherein the polydeoxyribonucleotide has a molecular weight in the range 15,000-30,000.

8. (previously amended) The pharmaceutical formulation according to claim 1 wherein one or more antioxidants are added.

9. (previously amended) The pharmaceutical formulation according to claim 1, wherein cationic surfactants containing one or more mono-, di-substituted amminic groups, or quaternary ammonium groups, are present, said quaternary ammonium groups containing one or more aliphatic chains with a number of carbon atoms ranging from 8 to 22.

10. (currently amended) The pharmaceutical formulation according to claim 1 wherein the molar ratio between the total amount of the liposome lipid(s) and a cationic surfactant ranges from 10:0.05 to 10:3.

11. (currently amended) The pharmaceutical formulation according to claim 10 wherein the phospholipids in the liposomes include phosphatidylcoline or phosphatidylethanolamine and a second and different lipid and the molar ratio of the phosphatidylocline or phosphatidylethanolamine: second lipid: cationic surfactant ~~surfactant~~ ranges from 9:1:0.05 to 7:3:3.

12. (currently amended) The pharmaceutical formulation according to claim 1 wherein the weight ratio between the liposome amount and the polydeoxyribo-nucleotides ~~active principle~~ ranges from 10:2 to 10:0.1.

Claims 13-18 (previously canceled)

19. (previously added) A method for treating inflammation in a patient in need thereof, comprising administering to the patient an antiflammatory effective amount of the pharmaceutical formulation according to claim 1.

20. (previously added) A method for treating thrombosis in a patient in need thereof, comprising administering to the patient an antithrombotic effective amount of the pharmaceutical formulation according to claim 1.

21. (previously added) A method for treating hypertension in a patient in need thereof, comprising administering to the patient an antihypertensive effective amount of the pharmaceutical formulation according to claim 1.

22. (previously added) A method for providing a sustained release of endothelial prostacyclin in a patient in need thereof, comprising administering to the patient a sustained release providing effective amount of the pharmaceutical formulation according to claim 1.